Russell Investments Group Ltd. Has $8.09 Million Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Russell Investments Group Ltd. increased its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 9.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 116,243 shares of the company’s stock after purchasing an additional 10,320 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.07% of Dr. Reddy’s Laboratories worth $8,088,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in Dr. Reddy’s Laboratories in the 4th quarter worth about $34,000. PDS Planning Inc increased its holdings in Dr. Reddy’s Laboratories by 6.3% in the fourth quarter. PDS Planning Inc now owns 5,239 shares of the company’s stock worth $365,000 after buying an additional 309 shares during the last quarter. CWM LLC raised its position in Dr. Reddy’s Laboratories by 37.9% during the fourth quarter. CWM LLC now owns 2,174 shares of the company’s stock valued at $151,000 after acquiring an additional 598 shares in the last quarter. Signaturefd LLC lifted its stake in Dr. Reddy’s Laboratories by 5.1% in the fourth quarter. Signaturefd LLC now owns 21,272 shares of the company’s stock valued at $1,480,000 after acquiring an additional 1,032 shares during the last quarter. Finally, Lindbrook Capital LLC grew its position in Dr. Reddy’s Laboratories by 19.1% in the fourth quarter. Lindbrook Capital LLC now owns 3,519 shares of the company’s stock worth $245,000 after acquiring an additional 565 shares in the last quarter. 14.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RDY. Jefferies Financial Group lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. StockNews.com downgraded Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Barclays raised their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $80.00.

Dr. Reddy’s Laboratories Stock Down 4.6 %

Dr. Reddy’s Laboratories stock opened at $71.44 on Wednesday. The firm has a market cap of $11.92 billion, a price-to-earnings ratio of 18.85, a P/E/G ratio of 1.88 and a beta of 0.57. The firm has a fifty day moving average price of $73.82 and a two-hundred day moving average price of $70.84. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $53.12 and a fifty-two week high of $77.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.